FDA
Conflicts of interest involving public policy
FDA to Approve PET Scan for Alzheimer’s?
America’s health care expenditure is about to go through the roof–without improving anyone’s health!
Read MoreFDA Acknowledges Caving to Influence Peddling–ReGen / ECT
Dr. Joshua Sharfstein, the FDA’s principal deputy commissioner, acknowledged: “The message here is that there were problems with the integrity of F.D.A.’s decision-making process that have solutions.”
Read MoreTop FDA Officials, Compromised by Conflicts of Interest
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
Read MoreDoes the FDA have the authority to trump the Declaration of Helsinki?
The FDA is sliding rapidly down the slippery slope, abandoning widely accepted, international ethical research standards articulated in the internationally accepted, Declaration of Helsinki–to facilitate commercial medical experiments.
Read MoreConflicts for FDA committee set to weigh risks of Seroquel_Philadelphia Inquirer
FDA officials who continue to run its powerful center for drug evaluation (CDER) have once again shown bad faith by appointing financially compromised doctors to the Psychopharmacologic Drugs Advisory Committee (PDAC) advisory panel.
Read MoreObama picks Duo to Run FDA: Dr Hamburg, Commissioner; Dr. Sharfstein Deputy
Dr. Margaret "Peggy" Hamburg, a former health commissioner in New York City, is the leading candidate to become FDA commissioner, the agency's top job, while Baltimore health chief Joshua Sharfstein is in line to become a deputy commissioner
Read MoreObama’s Health Plan Could be Hijacked by Industry Which Sees Good Business
The Washington Post suggests, the chance for success in overhauling US healthcare depends on President Obama's ability to keep the major–discordant–players on board.
Read MoreLetter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Read MoreLetter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
Read MoreHPV Vaccine Researcher Blasts Mandatory Marketing
Dr. Diane M. Harper, a lead researcher in the development of the humanpapilloma virus vaccine, who says giving the drug to 11-year-old girls "is a great big public health experiment."
Read MoreThe Health Care Racket_Paul Krugman NYT
"it's an arms race between insurers, who deploy software and manpower trying to find claims they can reject, and doctors and hospitals, who deploy their own forces in an effort to outsmart or challenge the insurers.
Read MoreNicotine Fix–Evidence of Collusion: Pharma-Govt Smoking Guidelines
"The federal government's campaign could discourage potential quitters who don't want to spend money on quitting aids or don't like the idea of treating their nicotine addiction with more nicotine."
Read More